Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide combined with carboplatin for neoadjuvant treatment of locally advanced cervical cancer
ChiCTR1900023822Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of arsenic trioxide, carboplatin and docetaxel in Cervical Cancer (CC) (3 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Efficacy evaluation. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
arsenic trioxidecarboplatindocetaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900023822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023822.